Enhancing cardiac function and hematological parameters in STEMI patients: evaluating the efficacy and safety of ticagrelor combined with prourokinase and reteplase thrombolysis

doi:10.5246/jcps.2024.12.082

Abstract

Abstract:

To compare the effects of ticagrelor combined with prourokinase and reteplase thrombolysis on cardiac function and blood-related indexes in patients with ST-segment elevation myocardial infarction (STEMI), 280 patients hospitalized between January 2017 and December 2021 were randomly assigned into two groups: the experimental group and the control group, each comprising 140 cases. The control group received ticagrelor combined with prourokinase thrombolysis, while the experimental group received ticagrelor combined with reteplase thrombolysis. The impact of these treatments on cardiac function and blood-related indexes in STEMI patients was assessed. Results revealed that CK-MB, AST, and LDH levels significantly decreased after 7 d of treatment compared to pre-treatment levels, with the experimental group exhibiting lower levels compared to the control group. Additionally, NT-proBNP levels decreased in both groups after 24 h of treatment, with the experimental group showing a greater reduction compared to the control group. Furthermore, LVEF and E/A values significantly increased after 7 d of treatment in both groups, while LVEDd and LVESd values notably decreased, indicating improved cardiac function in the experimental group compared to the control group. Following treatment, levels of PT, TT, and APTT increased in both groups, while FIB levels decreased significantly, with noticeable differences between the two groups. The incidence of major adverse cardiovascular events (MACE) in the experimental group was significantly lower compared to the control group, although the rate of mild bleeding did not significantly differ. In conclusion, the combination of ticagrelor and reteplase demonstrated superior efficacy in reducing myocardial enzyme and NT-proBNP levels, improving cardiac function, and enhancing safety compared to ticagrelor and prourokinase. These findings suggested that ticagrelor combined with reteplase thrombolysis held promise for clinical application.

Key words: ST segment elevation myocardial infarction, Thrombolysis, Cardiac function, Ticagrelor, Prourokinase, Reteplase

Supporting:

Dongjuan Wang, Jihong Chen. Enhancing cardiac function and hematological parameters in STEMI patients: evaluating the efficacy and safety of ticagrelor combined with prourokinase and reteplase thrombolysis[J]. Journal of Chinese Pharmaceutical Sciences, 2024, 33(12): 1129-1136.

Figures/Tables 6

Table 1. Comparison of general information between two groups (x ± s, %).

Table 2. Comparison of CK-MB, AST, and LDH levels between two groups before and after treatment (x ± s, U/L).

Table 3. Comparison of NT proBNP levels between two groups before and after treatment (pg/mL, x ± s).

Table 4. Comparison of cardiac function between two groups before and after treatment (x ± s, n = 140).

Table 5. Comparison of four coagulation results between two groups before and after treatment (x ± s, n = 140).

Table 6. Comparison of incidence of adverse events between two groups after treatment (x ± s, n = 140).

References 17

[1]	Yan, B.; Teng, S.M.; Niu, J.L.; Ma, Z.J.; Xu, Q. Evaluation of the degree and prognosis of coronary artery disease in elderly patients with acute ST segment elevation myocardial infarction by neutrophil to lymphocyte ratio. Chin. J. Geriatr. Cardiovasc. Cerebrovasc. Dis. 2022, 24, 385–388.
[2]	Zhu, J.; Chen, S.Y.; Wang, Y.; Xiao, J.; Liu, Y.C. Exploration of risk biomarkers for major adverse cardiovascular events in patients with ST segment elevation myocardial infarction after surgery. Chin. J. Geriatr. Cardiovasc. Dis. 2022, 24, 140–143.
[3]	Li, X.R.; Zuo, H.J.; Yang, H.X.; Zhang, D.F.; Ma, Z.; An, Z.Y.; Song, X.T. Clinical characteristics and prognosis of adult STEMI patients aged 35 and below. Chin. J. Cardiovasc. Dis. 2021, 49, 1124–1129.
[4]	Bai, M.; Pan, C.L.; Zhao, J.; Zhao, C.R.; Zhang, B.; Mu, Z.Y.; Meng, X.X.; Zhou, X.H.; Zhu, Y.Q.; Zhang, Z. Exploration of regional transport combined with PCI mode after thrombolysis in STEMI patients in northwest China. Chin. J. Geriatr. Cardiovasc. Dis. 2020, 48, 641–647.
[5]	Song, L.; Xu, D.Y.; Zhou, P.; Liu, C.; Sheng, Z.X.; Li, J.N.; Zhou, J.Y.; Chen,R.Z.; Chen,Y.; Zhao, H.J.; Yan, H.B. A preliminary study on the changes in serum uric acid levels and their impact on platelet reactivity in STEMI patients taking ticagrelor. Chin. J. Geriatr. Cardiovasc. Dis. 2021, 49, 170–175.
[6]	Hu, Y.C.; Chen, E.Y.; Yang, S.J.; Zhang, J.J.; Yu, M.M.; Feng, J. The application value of recombinant human prourokinase in PCI treatment of STEMI patients. Chin. J. Gerontol. 2022, 42, 772–775.
[7]	Shi, X.B.; Zhang, S.Y. Chinese expert consensus on the use of recombinant human tissue type plasminogen kinase derivative for thrombolytic therapy in acute ST segment elevation myocardial infarction. Chin. J. Int. Med. 2016, 55, 572–577.
[8]	Zhang, Y.; Wang, S.; Gao, C.Y.; Liu, X.Y.; Cheng, Q.Q.; Zhang, J.H.; Qi, D.T.; Wang, X.P.; Zhu, Z.Y.; Li, M.W.; Hu, D.Y. Comparison of the efficacy and safety of prourokinase and riteplase in the treatment of acute STEMI. Chin. J. Cardiovasc. Dis. 2021, 49, 866–872.
[9]	Yang, Y.J.; Yang, J.G. Interpretation of the Global Definition of Myocardial Infarction in the Third Edition. Chin. J. Circ. 2012, 27, 261–263.
[10]	Chinese Society of Cardiology. Chinese Journal of Cardiovascular Disease Editorial Committee. Guidelines for Diagnosis and Treatment of Acute ST Segment Elevated Myocardial Infarction. Chin. J. Cardiovasc. Dis. 2015, 43, 380–393.
[11]	Wang, H.B.; Gai, H.Z.; Wang, Y.X.; Su, Y.; Gao, X.L.; Liu, Y.H. The predictive value of the ratio of monocytes to high-density lipoprotein cholesterol for the prognosis of elderly patients with ST segment elevation myocardial infarction. Chin. J. Geriatr. Cardiovasc. Dis. 2022, 24, 47–50.
[12]	Han, Y.L.; Li, Y. Drug intervention combined therapy is an effective reperfusion strategy for STEMI patients. Chin. J. Cardiovasc. Dis. 2020, 48, 631–633.
[13]	Gao, Y.Y.; Wang, H.; Wan, D.Y.; Liu, Y.; Ji, J.R.; Zhang, S.H.; Ma, C.; Liu, H.L. Exploring the efficacy and safety of different P2Y12 receptor antagonists in elderly patients with acute coronary syndrome. Chin. J. Geriatr. Cardiovasc. Dis. 2020, 22, 314–316.
[14]	Na, K.; Li, M.Y.; Qiu, M.H.; Li, J.; Liu, R.; Li, Y.; Han, Y.L. Analysis of the efficacy and safety of using ticagrelor and clopidogrel after PCI in elderly ACS patients. Chin. J. Cardiovasc. Dis. 2021, 49, 1117–1123.
[15]	An, Q.; Zhao, J.; Liu, P.D.; Liu, Y.Y.; Guo, Y.M.; Guo, Y. The effects of electroacupuncture combined with salvianolic acid salts on cardiac function and drug tissue distribution in rats with acute myocardial infarction. Chin. J. Int. Tradit. Chin. West. Med. 2022, 42, 334–340.
[16]	Li, J.Q.; Dai, Q.X.; Han, J.X.; Chang, Q.; Li, Y. The therapeutic effect of Danhong injection combined with Qukrutin in the treatment of acute cerebral infarction and its effects on hs CRP and TNF- α And the impact of IL-6. Chin. J. Tradit. Chin. Med. 2019, 37, 2013–2016.
[17]	Chen, G.Y.; Ouyang, X.L.; Wu, J.H.; Wang, L.H.; Yang, J.H.; Gu, L.N.; Lu, Z.J.; Zhao, X.Z. Comparative study of thromboelastography and conventional coagulation four item evaluation of coagulation function in clinical patients. Chin. J. Exp. Hematol. 2015, 23, 546–551.